Background
D.C., then nineteen, was residing at the Colorado Mental Health Hospital in Pueblo after initially being admitted following a finding that he was incompetent to proceed in a criminal case. He had diagnoses including ADHD, intermittent explosive disorder, and mild intellectual disability. His symptoms included aggression, impulsivity, mood instability, hypervigilance, and occasional paranoia.
A voluntary regimen of risperidone and guanfacine had reduced D.C.’s aggression and impulsivity, but he periodically refused medication. During periods of nonadherence, he became agitated and assaultive, including by fighting with peers, damaging windows, and assaulting or charging toward staff. His psychiatrist sought authority to administer risperidone, guanfacine, and valproic acid involuntarily. The district court granted the request after finding the four requirements of People v. Medina satisfied by clear and convincing evidence.
The Court’s Holding
The Colorado Court of Appeals affirmed. It held that sufficient evidence supported the finding that no less intrusive effective alternative was available. Although D.C.’s psychiatrist said an Intuniv-only regimen might be possible and had not been tried, he could not say with confidence that it would work. The psychiatrist testified that risperidone and guanfacine together had effectively reduced D.C.’s anger and aggression and that a second medication remained clinically necessary while risperidone was tapered or evaluated.
The court also upheld authorization of Depakote as a backup medication. The psychiatrist sought that option in case D.C.’s reported vision problems were attributable to risperidone and D.C. continued to require more than one medication. Finally, the court held that D.C.’s vision-related concerns were a bona fide interest in declining risperidone, but the need to treat his symptoms and prevent serious harm to others at the hospital was sufficiently compelling to override that interest.
Key Takeaways
- A possible but untested single-drug regimen does not necessarily establish a less intrusive effective alternative.
- A court may authorize a backup medication when the treating psychiatrist identifies a concrete need for treatment flexibility.
- The risk of serious harm to people in an institution can outweigh a patient’s legitimate interest in refusing medication.
Why It Matters
The decision confirms that Colorado courts may consider both demonstrated treatment effectiveness and the need to respond to foreseeable side effects when applying Medina’s less-intrusive-alternative requirement. Clinical flexibility must be supported by evidence, but it need not be limited to a single medication where the record shows that combination treatment has been effective and safety risks persist.